191 related articles for article (PubMed ID: 36504019)
1. A performance comparison of two (electro) chemiluminescence immunoassays for detection and quantitation of serum anti-spike antibodies according to SARS-CoV-2 vaccination and infections status.
Camacho J; Albert E; Zulaica J; Álvarez-Rodríguez B; Rusu L; Olea B; Alcaraz MJ; Geller R; Giménez E; Navarro D
J Med Virol; 2023 Jan; 95(1):e28397. PubMed ID: 36504019
[TBL] [Abstract][Full Text] [Related]
2. Antibody-dependent NK-cell and neutralizing antibody responses against the Spike protein of Wuhan-Hu-1 and Omicron BA.1 SARS-CoV-2 variants in vaccinated experienced and vaccinated naïve individuals.
Albert E; Fernández-Soto D; Giménez E; Casanovas JM; Zulaica J; Álvarez-Rodríguez B; Rusu L; Geller R; Reyburn HT; Navarro D
J Med Virol; 2023 Jul; 95(7):e28900. PubMed ID: 37403730
[TBL] [Abstract][Full Text] [Related]
3. Cumulative incidence of SARS-CoV-2 infection in the general population of the Valencian Community (Spain) after the surge of the Omicron BA.1 variant.
Camacho J; Giménez E; Albert E; Zulaica J; Álvarez-Rodríguez B; Torres I; Rusu L; Burgos JS; Peiró S; Vanaclocha H; Limón R; Alcaraz MJ; Sánchez-Payá J; Díez-Domingo J; Comas I; Gonzáles-Candelas F; Geller R; Navarro D;
J Med Virol; 2023 Jan; 95(1):e28284. PubMed ID: 36333837
[TBL] [Abstract][Full Text] [Related]
4. Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays.
Valdivia A; Torres I; Latorre V; Francés-Gómez C; Albert E; Gozalbo-Rovira R; Alcaraz MJ; Buesa J; Rodríguez-Díaz J; Geller R; Navarro D
Eur J Clin Microbiol Infect Dis; 2021 Mar; 40(3):485-494. PubMed ID: 33404891
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays.
Chapuy-Regaud S; Miédougé M; Abravanel F; Da Silva I; Porcheron M; Fillaux J; Diméglio C; Izopet J
Microbiol Spectr; 2021 Dec; 9(3):e0137621. PubMed ID: 34937195
[TBL] [Abstract][Full Text] [Related]
6. Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre-pandemic controls.
Jung K; Shin S; Nam M; Hong YJ; Roh EY; Park KU; Song EY
J Clin Lab Anal; 2021 Sep; 35(9):e23921. PubMed ID: 34369009
[TBL] [Abstract][Full Text] [Related]
7. Current immunoassays and detection of antibodies elicited by Omicron SARS-CoV-2 infection.
Migueres M; Chapuy-Regaud S; Miédougé M; Jamme T; Lougarre C; Da Silva I; Pucelle M; Staes L; Porcheron M; Diméglio C; Izopet J
J Med Virol; 2023 Jan; 95(1):e28200. PubMed ID: 36207814
[TBL] [Abstract][Full Text] [Related]
8. A machine learning model for predicting serum neutralizing activity against Omicron SARS-CoV-2 BA.2 and BA.4/5 sublineages in the general population.
Camacho J; Albert E; Álvarez-Rodríguez B; Rusu L; Zulaica J; Moreno AR; Peiró S; Geller R; Navarro D; Giménez E
J Med Virol; 2023 Apr; 95(4):e28739. PubMed ID: 37185857
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays.
Seidel A; Hoffmann S; Jahrsdörfer B; Körper S; Ludwig C; Vieweg C; Albers D; von Maltitz P; Müller R; Lotfi R; Wuchter P; Klüter H; Kirchhoff F; Schmidt M; Münch J; Schrezenmeier H
Front Immunol; 2023; 14():1170759. PubMed ID: 37180152
[TBL] [Abstract][Full Text] [Related]
10. Rapid Quantitative Point-Of-Care Diagnostic Test for Post COVID-19 Vaccination Antibody Monitoring.
Moeller ME; Engsig FN; Bade M; Fock J; Pah P; Soerensen AL; Bang D; Donolato M; Benfield T
Microbiol Spectr; 2022 Apr; 10(2):e0039622. PubMed ID: 35357223
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection.
Torres I; Giménez E; Albert E; Zulaica J; Álvarez-Rodríguez B; Burgos JS; Peiró S; Limón R; Vanaclocha H; Rodado C; Botija P; Sifre A; Tur B; Lozano RA; Orosa I; Vicente-Ruiz M; Carrión RJ; Clari MÁ; Sánchez-Payá J; Díez-Domingo J; Comas I; González-Candelas F; Geller R; Navarro D;
J Med Virol; 2022 Sep; 94(9):4216-4223. PubMed ID: 35585782
[TBL] [Abstract][Full Text] [Related]
12. Validation of N Protein Antibodies to Diagnose Previous SARS-CoV-2 Infection in a Large Cohort of Healthcare Workers: Use of Roche Elecsys
Delgado JF; Vidal M; Julià G; Navarro G; Serrano RM; van den Eynde E; Navarro M; Calvet J; Gratacós J; Espasa M; Peña P
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112910
[TBL] [Abstract][Full Text] [Related]
13. Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays.
Perkmann T; Perkmann-Nagele N; Koller T; Mucher P; Radakovics A; Marculescu R; Wolzt M; Wagner OF; Binder CJ; Haslacher H
Microbiol Spectr; 2021 Sep; 9(1):e0024721. PubMed ID: 34190591
[TBL] [Abstract][Full Text] [Related]
14. Comparison of SARS-CoV-2 spike antibody quantitative titer reporting using the World Health Organization International Standard Units by four commercial assays.
Zhuo R; Charlton C; Plitt S; Thompson LA; Braun S; Day J; Osiowy C; Tipples G; Kanji JN
J Clin Virol; 2022 Nov; 156():105292. PubMed ID: 36108404
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals.
Hayer J; Urlaub E
Microbiol Spectr; 2022 Jun; 10(3):e0270921. PubMed ID: 35575594
[TBL] [Abstract][Full Text] [Related]
16. Dissection of Antibody Responses of Gam-COVID-Vac-Vaccinated Subjects Suggests Involvement of Epitopes Outside RBD in SARS-CoV-2 Neutralization.
Byazrova M; Gattinger P; Astakhova E; Hofer G; Khaitov M; Filatov A; Valenta R
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982183
[TBL] [Abstract][Full Text] [Related]
17. Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world.
Li M; Jiang R; Wang E; Xiong D; Ou T; Zhang X; Dou X
BMC Infect Dis; 2022 Feb; 22(1):157. PubMed ID: 35168557
[TBL] [Abstract][Full Text] [Related]
18. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays.
Padoan A; Cosma C; Bonfante F; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Pagliari M; Bortolami A; Cattelan A; Cianci V; Basso D; Plebani M
Clin Chem Lab Med; 2022 Feb; 60(3):456-463. PubMed ID: 34911170
[TBL] [Abstract][Full Text] [Related]
20. Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects.
Cristiano A; Nuccetelli M; Pieri M; Sarubbi S; Pelagalli M; Calugi G; Tomassetti F; Bernardini S
Int Immunopharmacol; 2021 Dec; 101(Pt B):108215. PubMed ID: 34649115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
